MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema

Molecular Endocrinology

Volumn 23, Issue 7, 2009, Pages 975-988

  Gregoire, Francine M ^a   Zhang, Fang ^b   Clarke, Holly J ^a,f   Gustafson, Thomas A ^c   Sears, Dorothy D ^d   Favelyukis, Svetlana ^d   Lenhard, James ^e   Rentzeperis, Dennis ^e   Clemens, L Edward ^a   Mu, Yi ^a   Lavan, Brian E ^a  

^a Metabolex ^*  (United States)

^b ELI LILLY AND COMPANY   (United States)

^c PFIZER INC   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e Johnson and Johnson PRD   (United States)

^f GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; METAGLIDASEN; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TESAGLITAZAR; TROGLITAZONE;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; EDEMA; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN SENSITIVITY; MALE; MESENCHYME CELL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; RAT; WEIGHT GAIN;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; DRUG PARTIAL AGONISM; EDEMA; HALOFENATE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; PPAR GAMMA; RATS; RATS, ZUCKER; STEREOISOMERISM; SUBSTRATE SPECIFICITY; THIAZOLIDINEDIONES; TRANSCRIPTIONAL ACTIVATION; WEIGHT GAIN;

MURINAE; RODENTIA;

EID: 67649598394     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2008-0473     Document Type: Article

References (66)

1. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL 2002 Divergent effects of selective peroxisome proliferator-activated receptor-γ 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143:2376-2384
2. Ricote M, Glass CK 2007 PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 1771:926-935 (Pubitemid 47198544)
3. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM 1997 Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc Natl Acad Sci USA 94:4318-4323 (Pubitemid 27194239)
4. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B 2007 Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 1771:1065-1081 (Pubitemid 47208546)
5. Rosenfeld MG, Lunyak VV, Glass CK 2006 Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev 20:1405-1428 (Pubitemid 43830648)
6. Glass CK, Rosenfeld MG 2000 The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14:121-141 (Pubitemid 30070977)
7. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV 1998 Ligand binding and coactivator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395:137-143 (Pubitemid 28425645)
8. Burgermeister E, Schnoebelen A, Flament A, Benz J, Stihle M, Gsell B, Rufer A, Ruf A, Kuhn B, Märki HP, Mizrahi J, Sebokova E, Niesor E, Meyer M 2006 A novel partial agonist of peroxisome proliferator-activated receptor-γ (PPARγ) recruits PPARγ-coactivator-1α, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol Endocrinol 20:809-830
9. Einstein M, Akiyama TE, Castriota GA, Wang CF, McKeever B, Mosley RT, Becker JW, Moller DE, Meinke PT, Wood HB, Berger JP 2008 The differential interactions of peroxisome proliferator-activated receptor γ ligands with Tyr473 is a physical basis for their unique biological activities. Mol Pharmacol 73:62-74 (Pubitemid 350294197)
10. Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, Cobb JE, Lenhard JM, Hull-Ryde EA, Mohr CP, Blanchard SG, Parks DJ, Moore LB, Lehmann JM, Plunket K, Miller AB, Milburn MV, Kliewer SA, Willson TM 1999 A peroxisome proliferator-activated receptor γ ligand inhibits adipocyte differentiation. Proc Natl Acad Sci USA 96:6102-6106 (Pubitemid 29256626)
11. Picard F, Auwerx J 2002 PPARγ and glucose homeostasis. Annu Rev Nutr 22:167-197 (Pubitemid 35221458)
12. Gurnell M, Savage DB, Chatterjee VK, O'Rahilly S 2003 The metabolic syndrome: peroxisome proliferator-activated receptor γ and its therapeutic modulation. J Clin Endocrinol Metab 88:2412-2421 (Pubitemid 36724405)
13. Grey A 2008 Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 19:129-137
14. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR 2008 Use of thiazolidinediones and fracture risk. Arch Intern Med 168:820-825 (Pubitemid 351620084)
15. Schwartz AV 2008 TZDs and bone: a review of the recent clinical evidence. PPAR Res 2008:297893
16. Shearer BG, Billin AN 2007 The next generation of PPAR drugs: do we have the tools to find them? Biochim Biophys Acta 1771:1082-1093
17. Pascual G, Sullivan AL, Ogawa S, Gamliel A, Perissi V, Rosenfeld MG, Glass CK 2007 Anti-inflammatory and antidiabetic roles of PPARγ. Novartis Found Symp 286:183-196; discussion 196-203
18. Straus DS, Glass CK 2007 Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 28:551-558 (Pubitemid 350101420)
19. Széles L, Tö rö csik D, Nagy L 2007 PPARγ in immunity and inflammation: cell types and diseases. Biochim Biophys Acta 1771:1014-1030
20. Hevener AL, Olefsky JM, Reichart D, Nguyen MT, Bandyopadyhay G, Leung HY, Watt MJ, Benner C, Febbraio MA, Nguyen AK, Folian B, Subramaniam S, Gonzalez FJ, Glass CK, Ricote M 2007 Macrophage PPAR γ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest 117:1658-1669 (Pubitemid 46871350)
21. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, Red Eagle A, Vats D, Brombacher F, Ferrante AW, Chawla A 2007 Macrophage-specific PPARγ controls alternative activation and improves insulin resistance. Nature 447:1116-1120 (Pubitemid 47014427)
22. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK 2005 A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 437:759-763 (Pubitemid 41486547)
23. Carmona MC, Louche K, Lefebvre B, Pilon A, Hennuyer N, Audinot-Bouchez V, Fievet C, Torpier G, Formstecher P, Renard P, Lefebvre P, Dacquet C, Staels B, Casteilla L, Pénicaud L 2007 S 26948: a new specific peroxisome proliferator activated receptor γ modulator with potent antidiabetes and antiatherogenic effects. Diabetes 56:2797-2808 (Pubitemid 350044924)
24. Einstein M, Akiyama TE, Castriota GA, Wang CF, McKeever B, Mosley R, Becker JW, Moller DE, Meinke PT, Wood HB, Berger JP 2008 The differential interactions of PPARγ ligands with tyrosine 473 is a physical basis for their unique biological activities. Mol Pharmacol 73:62-74
25. Gelman L, Feige JN, Desvergne B 2007 Molecular basis of selective PPARγ modulation for the treatment of type 2 diabetes. Biochim Biophys Acta 1771:1094-1107 (Pubitemid 47214561)
26. Chang F, Jaber LA, Berlie HD, O'Connell MB 2007 Evolution of peroxisome proliferator-activated receptor agonists. Ann Pharmacother 41:973-983 (Pubitemid 46917624)
27. Zhang F, Lavan BE, Gregoire FM 2007 Selective modulators of PPAR-γ activity: molecular aspects related to obesity and side-effects. PPAR Res 2007:32696
28. Aronow WS, Vangrow JS, Nelson WH, Pagano J, Papageorge's NP, Khursheed M, Harding PR, Khemka M 1973 Halofenate: an effective hypolipemia- and hypouricemia-inducing drug. Curr Ther Res Clin Exp 15:902-906
29. Feldman EB, Gluck FB, Carter AC 1978 Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia. J Clin Pharmacol 18:241-248 (Pubitemid 8384291)
30. Krut LH, Seftel HC, Joffe BI 1977 Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia. S Afr Med J 51:348-352 (Pubitemid 8059986)
31. Allen T, Zhang F, Moodie SA, Clemens LE, Smith A, Gregoire F, Bell A, Muscat GE, Gustafson TA 2006 Halofenate is a selective peroxisome proliferator- activated receptor γ modulator with antidiabetic activity. Diabetes 55:2523-2533 (Pubitemid 44871152)
32. Bruning JB, Chalmers MJ, Prasad S, Busby SA, Kamenecka TM, He Y, Nettles KW, Griffin PR 2007 Partial agonists activate PPARγ using a helix 12 independent mechanism. Structure 15:1258-1271 (Pubitemid 47539157)
33. Arakawa K, Ishihara T, Aoto M, Inamasu M, Kitamura K, Saito A 2004 An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats. Clin Exp Pharmacol Physiol 31:8-13 (Pubitemid 38230742)
34. Yu S, Reddy JK 2007 Transcription coactivators for peroxisome proliferatoractivated receptors. Biochim Biophys Acta 1771:936-951 (Pubitemid 47198542)
35. Rosenstock J, Flores-Lozano F, Schartz S., Gonzalez-Galvez G, Karpf D 2005 MBX-102: a novel non-TZD insulin sensitizer that improves glycemic control without causing edema or weight gain in patients with type 2 diabetes (T2DM) on concomitant insulin therapy. Diabetes 54:44-OR (Abstract)
36. Fukui Y, Masui S, Osada S, Umesono K, Motojima K 2000 A new thiazolidinedione, NC-2100, which is a weak PPAR-γ activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes 49:759-767 (Pubitemid 30339991)
37. Kim KR, Lee JH, Kim SJ, Rhee SD, Jung WH, Yang SD, Kim SS, Ahn JH, Cheon HG 2006 KR-62980: A novel peroxisome proliferator-activated receptor γ agonist with weak adipogenic effects. Biochem Pharmacol 72:446-454 (Pubitemid 44081772)
38. Ostberg T, Svensson S, Selén G, Uppenberg J, Thor M, Sundbom M, Sydow- Bäckman M, Gustavsson AL, Jendeberg L 2004 A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. J Biol Chem 279:41124-41130 (Pubitemid 39287714)
39. Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Tanaka H, Lazar MA 1998 A potent antidiabetic thiazolidinedione with unique peroxisome proliferator- activated receptor γ-activating properties. J Biol Chem 273:32679-32684 (Pubitemid 28557651)
40. Rocchi S, Picard F, Vamecq J, Gelman L, Potier N, Zeyer D, Dubuquoy L, Bac P, Champy MF, Plunket KD, Leesnitzer LM, Blanchard SG, Desreumaux P, Moras D, Renaud JP, Auwerx J 2001 A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 8:737-747 (Pubitemid 33030208)
41. Bays H, Mandarino L, DeFronzo RA 2004 Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89:463-478 (Pubitemid 38269844)
42. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA 2001 Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 44:2210-2219 (Pubitemid 34015474)
43. Miyazaki Y, Glass L, Triplitt C, Wajcberg E, Mandarino LJ, DeFronzo RA 2002 Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 283:E1135-E1143 (Pubitemid 35340618)
44. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA 2002 Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87:2784-2791 (Pubitemid 34655345)
45. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, Ikeda Y 1999 Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 22:908-912 (Pubitemid 29241043)
46. Kawai T, Takei I, Oguma Y, Ohashi N, Tokui M, Oguchi S, Katsukawa F, Hirose H, Shimada A, Watanabe K, Saruta T 1999 Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism 48:1102-1107 (Pubitemid 29418278)
47. Kelly IE, Han TS, Walsh K, Lean ME 1999 Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22:288-293 (Pubitemid 29056924)
48. Boden G, Cheung P, Mozzoli M, Fried SK 2003 Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metabolism 52:753-759 (Pubitemid 36896311)
49. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T 1998 Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354-1361 (Pubitemid 28145252)
50. Bogacka I, Ukropcova B, McNeil M, Gimble JM, Smith SR 2005 Structural and functional consequences of mitochondrial biogenesis in human adipocytes in vitro. J Clin Endocrinol Metab 90:6650-6656 (Pubitemid 41759328)
51. Bogacka I, Xie H, Bray GA, Smith SR 2005 Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 54:1392-1399 (Pubitemid 40586669)
52. Wilson-Fritch L, Nicoloro S, Chouinard M, Lazar MA, Chui PC, Leszyk J, Straubhaar J, Czech MP, Corvera S 2004 Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest 114:1281-1289 (Pubitemid 40385299)
53. Feige JN, Auwerx J 2007 Transcriptional coregulators in the control of energy homeostasis. Trends Cell Biol 17:292-301 (Pubitemid 46829846)
54. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL 2005 Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146:1226-1235 (Pubitemid 40289310)
55. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B 2007 Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148:2669-2680 (Pubitemid 46984815)
56. Paulik MA, Lenhard JM 1997 Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells. Cell Tissue Res 290:79-87 (Pubitemid 27460128)
57. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B 2004 Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401-406 (Pubitemid 38094536)
58. Sottile V, Seuwen K, Kneissel M 2004 Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARγ agonist BRL49653 (rosiglitazone). Calcif Tissue Int 75:329-337 (Pubitemid 40064235)
59. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR 2007 The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 92:1305-1310 (Pubitemid 46556402)
60. Hampton T 2007 Diabetes drugs tied to fractures in women. JAMA 297:1645 (Pubitemid 46631642)
61. Meymeh RH, Wooltorton E 2007 Diabetes drug pioglitazone (Actos): risk of fracture. Can Med Assoc J 177:723-724
62. Wan Y, Chong LW, Evans RM 2007 PPAR-γ regulates osteoclastogenesis in mice. Nat Med 13:1496-1503 (Pubitemid 350224244)
63. Shoelson SE, Herrero L, Naaz A 2007 Obesity, inflammation, and insulin resistance. Gastroenterology 132:2169-2180 (Pubitemid 46693756)
64. Stienstra R, Duval C, Keshtkar S, van der Laak J, Kersten S, Mü ller M 2008 PPARγ activation promotes infiltration of alternatively activated macrophages into adipose tissue. J Biol Chem 283:22620-22627
65. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK 2003 PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages. Proc Natl Acad Sci USA 100:6712-6717 (Pubitemid 36666645)
66. Katayama K, Wada K, Miyoshi H, Ohashi K, Tachibana M, Furuki R, Mizuguchi H, Hayakawa T, Nakajima A, Kadowaki T, Tsutsumi Y, Nakagawa S, Kamisaki Y, Mayumi T 2004 RNA interfering approach for clarifying the PPARγ pathway using lentiviral vector expressing short hairpin RNA. FEBS Lett 560:178-182 (Pubitemid 38264314)